![© Getty Images](https://cdn.statically.io/img/www.biopharma-reporter.com/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_large/publications/pharmaceutical-science/biopharma-reporter.com/hot-topics/antibody-drug-conjugates/phase-2-failure-for-novovirus-vaccine/17576359-1-eng-GB/Phase-2-failure-for-novovirus-vaccine.jpg)
HilleVax halts development of world’s most advanced norovirus vaccine after phase 2 failure
Results from the NEST-IN1 trial have shown that HilleVax’s vaccine candidate was ineffective at preventing norovirus infections in infants.
Results from the NEST-IN1 trial have shown that HilleVax’s vaccine candidate was ineffective at preventing norovirus infections in infants.